References: 1. Biosimilars Resource Center. What are biologics? www.biosimilarsresourcecenter.org/faq/what-are-biologics/. Accessed October 29, 2019. 2. Sathish JG, Sethu S, Bielsky MC, et al. Challenges and approaches for the development of safer immunomodulatory biologics. Nat Rev Drug Discov. 2013;12:206-324. 3. US Food and Drug Administration. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. www.fda/gov/downloads/drugs/guidances.ucm291128.pdf. Accessed October 29, 2019. 4. Boccia R, Jacobs I, Popovian R, de Lima Lopes G Jr. Can biosimilars help achieve the goals of US health care reform? Cancer Manag Res. 2017;9:197-205.
HK-09630-AMGEN-2022-Dec Date of approval: 2022年12月